Cargando…

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels are reported. Induction therapy consisted of four cy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wester, Ruth, van der Holt, Bronno, Asselbergs, Emelie, Zweegman, Sonja, Kersten, Marie Jose, Vellenga, Edo, van Marwijk Kooy, Marinus, de Weerdt, Okke, Minnema, Monique, Lonergan, Sarah, Palumbo, Antonio, Lokhorst, Henk, Broijl, Annemiek, Sonneveld, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821616/ https://www.ncbi.nlm.nih.gov/pubmed/30948492 http://dx.doi.org/10.3324/haematol.2018.205476

Ejemplares similares

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
por: Wester, Ruth, et al.
Publicado: (2020)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
por: Wester, Ruth, et al.
Publicado: (2022)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: Minnema, Monique, et al.
Publicado: (2023)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
por: Fokkema, Cathelijne, et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
por: van den Heuvel-Eibrink, Marry M., et al.
Publicado: (2007)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020)

Rethinking thalidomide.
Publicado: (1995)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
por: Ubels, Joske, et al.
Publicado: (2018)

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
por: van de Donk, N., et al.
Publicado: (2023)

Thalidomide in Dermatology: Revisited
por: Hassan, Iffat, et al.
Publicado: (2015)

Death and Rebirth of the Thalidomide Molecule: A Case of Thalidomide-Induced Sensory Neuropathy
por: Kesserwani, Hassan
Publicado: (2021)

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
por: Hofste op Bruinink, Davine, et al.
Publicado: (2022)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
por: Groen, K., et al.
Publicado: (2022)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis
por: Eigbire-Molen, Odianosen, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
por: Barla, Ioanna, et al.
Publicado: (2022)

Convergence of Hypoxia and TGFβ Pathways on Cell Cycle Regulation in Human Hematopoietic Stem/Progenitor Cells
por: Wierenga, Albertus T. J., et al.
Publicado: (2014)

ELMO1 Is Upregulated in AML CD34+ Stem/Progenitor Cells, Mediates Chemotaxis and Predicts Poor Prognosis in Normal Karyotype AML
por: Capala, Marta E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_otdpfu91mes334sobs0hjna2n8